Gene
Therapy Market is projected to grow at an annualized rate of 45%, till 2030
Encouraging
clinical results across various metabolic, hematological and ophthalmic
disorders have inspired research groups across the world to focus their efforts
on the development of novel gene editing therapies. In fact, the gene therapy
pipeline has evolved significantly over the past few years, with three products
being approved in 2019 alone; namely Beperminogene perplasmid (AnGes),
ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio).
Further, there are multiple pipeline candidates in mid to
late-stage (phase II and above) trials that are anticipated to enter the market
over the next 5-10 years.
The
USD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market
has been analyzed across the following segments:
Read
Detailed Report: https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
